Company news
Cellectar Biosciences, Inc. (NASDAQ:CLRB) news
Every Cellectar Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 13, 2026
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
July 30, 2026
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
July 15, 2026
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Mac...
June 1, 2026
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
May 11, 2026
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficac...
May 5, 2026
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical On...
April 21, 2026
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Bre...
April 14, 2026
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
March 4, 2026
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
February 25, 2026
Cellectar Biosciences Expands Global Intellectual Property Estate
February 17, 2026
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Co...
January 9, 2026
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Thera...
December 16, 2025
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
November 6, 2025
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed...
October 27, 2025
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) ...
October 14, 2025
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
October 7, 2025
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA...
October 6, 2025
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Spe...
September 30, 2025
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breas...
September 24, 2025
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
September 11, 2025
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
September 9, 2025
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
September 5, 2025
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advanc...
September 3, 2025
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Confe...
August 27, 2025
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
August 14, 2025
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
August 7, 2025
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
July 2, 2025
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
July 1, 2025
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
June 26, 2025
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Br...
June 24, 2025
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
June 18, 2025
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refracto...
June 11, 2025
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
June 5, 2025
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
June 4, 2025
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
May 13, 2025
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
May 7, 2025
Cellectar Announces Plan to Explore Strategic Alternatives
April 30, 2025
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
March 13, 2025
Cellectar Biosciences to Present at the 37th Annual Roth Conference
March 11, 2025
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
March 5, 2025
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 5, 2025
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
January 12, 2025
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
December 10, 2024
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
November 21, 2024
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
November 18, 2024
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
November 14, 2024
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
November 12, 2024
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
November 11, 2024